

DMD #78162

**Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7,  
UGT2B4 and UGT2B17:  
Implications for Pharmacogenetics and Drug-Drug Interactions**

Helinä Kahma, Anne M. Filppula, Mikko Neuvonen, E. Katriina Tarkiainen, Aleksi Tornio, Mikko  
T. Holmberg, Matti K. Itkonen, Moshe Finel, Pertti J. Neuvonen, Mikko Niemi  
and Janne T. Backman

Department of Clinical Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki,  
Finland (H.K., A.M.F., M.Ne., E.K.T., A.T., M.T.H., M.K.I., P.J.N., M.Ni., J.T.B.); Helsinki  
University Hospital, Helsinki, Finland (E.K.T., A.T., M.T.H., M.K.I., P.J.N., M.Ni., J.T.B.);  
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of  
Helsinki, Helsinki, Finland (M.F.)

DMD #78162

**Running title:** Clopidogrel carboxylic acid glucuronidation

**Corresponding author:** Janne T. Backman, Department of Clinical Pharmacology, University of Helsinki, Biomedicum 2C, Tukholmankatu 8 C, 00290 Helsinki, Finland

Phone: +358 50 428 0997, Fax: +358 9 471 74039, Email: [janne.backman@helsinki.fi](mailto:janne.backman@helsinki.fi)

**Number of text pages:** 38

**Number of tables:** 2

**Number of figures:** 7

**Number of references:** 54

**Number of words:**

Abstract: 249

Introduction: 479

Discussion: 1086

**Abbreviations:** AUC<sub>0-4</sub>, area under the plasma concentration–time curve from 0 h to 4 h; CES, carboxylesterase; CI, confidence interval; CL<sub>int</sub>, intrinsic clearance; C<sub>max</sub>, peak plasma concentration; CYP, cytochrome P450; HIM, human intestine microsomes; HLM, human liver microsomes; k<sub>dep</sub>, pseudo-first-order depletion rate constant; K<sub>m</sub>, Michaelis–Menten constant; SNV, single nucleotide variation; t<sub>1/2</sub>, elimination half-life; t<sub>max</sub>, time at which peak plasma concentration occurs; UDPGA, uridine diphosphate glucuronic acid; UGT, UDP-glucuronosyltransferase.

DMD #78162

## Abstract

The antiplatelet drug clopidogrel is metabolized to an acyl- $\beta$ -D-glucuronide, which causes time-dependent inactivation of CYP2C8. Our aim was to characterize the UDP-glucuronosyltransferase (UGT) enzymes that are responsible for the formation of clopidogrel acyl- $\beta$ -D-glucuronide. Kinetic analyses and targeted inhibition experiments were performed using pooled human liver and intestine microsomes (HLM and HIM, respectively) and selected human recombinant UGTs based on preliminary screening. The effects of relevant *UGT* polymorphisms on the pharmacokinetics of clopidogrel were evaluated in 106 healthy volunteers. UGT2B7 and UGT2B17 exhibited the highest clopidogrel carboxylic acid glucuronidation activities, with a  $CL_{int,u}$  of 2.42 and 2.82  $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ , respectively. Of other enzymes displaying activity (UGT1A3, UGT1A9, UGT1A10-H and UGT2B4), UGT2B4 ( $CL_{int,u}$  0.51  $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ ) was estimated to contribute significantly to the hepatic clearance. Nonselective UGT2B inhibitors strongly inhibited clopidogrel acyl- $\beta$ -D-glucuronide formation in HLM and HIM. The UGT2B17 inhibitor imatinib and the UGT2B7 and UGT1A9 inhibitor mefenamic acid inhibited clopidogrel carboxylic acid glucuronidation in HIM and HLM, respectively. Incubation of clopidogrel carboxylic acid in HLM with UDPGA and NADPH resulted in strong inhibition of CYP2C8 activity. In healthy volunteers, *UGT2B17*\*2 deletion allele was associated with a 10% decrease per copy in the plasma clopidogrel acyl- $\beta$ -D-glucuronide to clopidogrel carboxylic acid  $AUC_{0-4}$  ratio ( $P < 0.05$ ). To conclude, clopidogrel carboxylic acid is mainly metabolized by UGT2B7 and UGT2B4 in the liver, and by UGT2B17 in the small intestinal wall. The formation of clopidogrel acyl- $\beta$ -D-glucuronide is impaired in carriers of the *UGT2B17* deletion. The findings may have implications regarding intracellular mechanisms leading to CYP2C8 inactivation by clopidogrel.

DMD #78162

## Introduction

The platelet P2Y<sub>12</sub> adenosine diphosphate receptor inhibitor clopidogrel is widely used to reduce blood clotting in patients at high risk for vascular thrombotic events. Due to its complex pharmacokinetic profile, clopidogrel is susceptible to various drug-drug interactions and genetic polymorphisms resulting in variable drug response (Mega et al., 2009; Floyd et al., 2012; Frelinger et al., 2012; Tornio et al., 2014; Tarkiainen et al., 2015). Clopidogrel is a prodrug that is metabolized via two distinct routes. Approximately 10% of the absorbed dose undergoes a two-step oxidative metabolism pathway, producing the active *cis* 5-thiol metabolite, while the majority of the dose is metabolized by sequential hydrolysis and conjugation reactions into pharmacodynamically inactive clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide (Savi et al., 2000; Tang et al., 2006; Hagihara et al., 2009; Silvestro et al., 2011) (Figure 1).

The oxidative metabolism of clopidogrel is catalyzed by several cytochrome P450 (CYP) isoforms, including CYP2C19, CYP1A2, CYP2B6 and CYP3A4/5 (Clarke and Waskell, 2003; Hagihara et al., 2009; Kazui et al., 2010; Dansette et al., 2012). The *CYP2C19* loss-of-function alleles are associated with low plasma concentrations of the active metabolite and poor clopidogrel responsiveness (Hulot et al., 2006; Giusti et al., 2007; Sibbing et al., 2009; Simon et al., 2009; Hochholzer et al., 2010). Interestingly, clopidogrel is also a mechanism-based inhibitor of CYP2C19 and CYP2B6 (Richter et al., 2004; Nishiya et al., 2009). In healthy volunteers, pretreatment with clopidogrel significantly increased the area under the plasma concentration-time curve (AUC) of omeprazole in subjects with homozygous *CYP2C19* extensive metabolizer genotype and the AUC of the CYP2B6 substrate bupropion (Turpeinen et al., 2005; Chen et al., 2009). The tendency to form reactive metabolites that irreversibly inactivate CYP enzymes has recently been observed also for the secondary metabolite, clopidogrel acyl- $\beta$ -D-glucuronide. This glucuronide metabolite was shown to be a strong mechanism-based inhibitor of CYP2C8, leading to

DMD #78162

a marked increase in the plasma concentrations of repaglinide and pioglitazone (Tornio et al., 2014; Itkonen et al., 2016).

The hydrolysis of clopidogrel into clopidogrel carboxylic acid is catalyzed by carboxylesterase 1 (CES1) (Tang et al., 2006), as demonstrated clinically by the increased antiplatelet effects of clopidogrel in carriers of a loss-of-function single nucleotide variant of *CES1* (Tarkiainen et al., 2015). What is not known, yet, is which UGT enzymes catalyse the glucuronidation of clopidogrel carboxylic acid into clopidogrel acyl- $\beta$ -D-glucuronide. Identifying the UGT enzymes responsible for this activity is particularly interesting since the metabolic pathway leads to the formation of a bioactive glucuronide metabolite that inactivates CYP2C8. To this end, we carried out an *in vitro* study to elucidate the role of 13 human UGTs in the formation of clopidogrel acyl- $\beta$ -D-glucuronide. Moreover, to gain insight into the clinical relevance of the findings, we investigated the effects of common variants in relevant *UGT* genes on the pharmacokinetics of clopidogrel carboxylic acid glucuronidation in a population comprising healthy volunteers from previous and ongoing pharmacokinetic studies.

DMD #78162

## Materials and Methods

### Materials

Pooled HLM (UltraPool), pooled HIM, and microsomes from baculovirus infected insect cells expressing recombinant human UGT isoforms (Supersomes) were purchased from Corning (Corning, NY, USA), except for His-tagged UGT1A10 (UGT1A10-H) which was prepared in Helsinki as previously described (Kuuranne et al., 2003). The rapid equilibrium dialysis device (RED®) was obtained from Thermo Scientific (Waltham, MA, USA). Aprepitant, S-(+)-clopidogrel hydrogen sulfate, (+/-)-clopidogrel carboxylic acid, (+/-)-clopidogrel-d4 carboxylic acid, gemfibrozil, N-desethylamodiaquine hydrochloride and N-desethylamodiaquine-d5 were purchased from Toronto Research Chemicals (North York, ON, Canada). Amodiaquine dihydrochloride dihydrate, (+/-)-ketamine hydrochloride,  $\beta$ -NADPH and UDPGA were from Sigma-Aldrich (St. Louis, MO, USA). Clopidogrel acyl- $\beta$ -D-glucuronide was obtained from Santa Cruz Biotechnology (Dallas, TX, USA), fluconazole and mefenamic acid were from Pfizer (Sandwich, UK) and imatinib mesylate was from Sequoia Research Products, (Pangbourne, UK). Other solvents and reagents were of analytical grade.

### *In Vitro* Study

UGT Incubation Conditions. Human recombinant UGTs (hrUGTs), pooled human liver microsomes (HLM) or pooled human intestinal microsomes (HIM) were diluted in 0.1 M sodium phosphate buffer (pH 7.4) containing  $\text{MgCl}_2$  (10 mM). In addition, the pore forming peptide alamethicin ( $10 \mu\text{g} \cdot \text{mL}^{-1}$ ) was added to incubation mixtures containing HLM or HIM. The protein concentrations in hrUGT, HLM and HIM incubations ranged from 0.2 to 0.8  $\text{mg} \cdot \text{mL}^{-1}$ , as described for each assay below. Clopidogrel carboxylic acid concentration ranged from 0.5 to 3000

DMD #78162

$\mu\text{M}$ , depending on the experiment. HLM and HIM incubation mixtures were kept on ice for 20 minutes before preincubation to allow pore formation by alamethicin. For consistency, the same treatment was applied to hrUGT incubations. The incubation mixtures were then moved to a heated shaker and preincubated for 5 minutes (at  $37^{\circ}\text{C}$ , 300 rpm), followed by addition of 5 mM uridine-diphosphate glucuronic acid (UDPGA) to initiate the reactions. Incubations were terminated after a designated time by mixing one part reaction mixture with three parts acetonitrile containing clopidogrel-d4 carboxylic acid as an internal standard. Samples were vortexed and cooled on ice for at least 10 minutes before centrifugation ( $20\,800 \times g$  for 10 min). Finally, the supernatants were transferred to HPLC microvials for LC/MS/MS analysis. The non-specific binding of  $0.5 \mu\text{M}$  clopidogrel carboxylic acid to HLM ( $0.4$  and  $0.8 \text{ mg} \cdot \text{mL}^{-1}$ ) and HIM ( $0.2 \text{ mg} \cdot \text{mL}^{-1}$ ), 1 and  $30 \mu\text{M}$  clopidogrel carboxylic acid to hrUGT2B17 ( $0.2 \text{ mg} \cdot \text{mL}^{-1}$ ) and  $100 \mu\text{M}$  clopidogrel to HLM and HIM ( $0.8 \text{ mg} \cdot \text{mL}^{-1}$ ) was determined by equilibrium analysis using the rapid equilibrium dialysis method. The fraction unbound was at least 0.8 in all incubations. Substrate and inhibitor compounds were dissolved in acetonitrile and methanol, respectively. The final solvent concentrations in incubations were 1% or less. All incubations were performed in duplicates.

***UGT Screening.*** To identify the specific UGTs responsible for clopidogrel carboxylic acid metabolism, glucuronidation was tested in human recombinant UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, His-tagged UGT1A10 (UGT1A10-H), UGT2B4, UGT2B7, UGT2B10, UGT2B15 and UGT2B17 at a final protein concentration of  $0.4 \text{ mg} \cdot \text{mL}^{-1}$ . In this experiment, clopidogrel carboxylic acid ( $10 \mu\text{M}$ ) was incubated with each UGT enzyme for 30 and 90 minutes as described above.

DMD #78162

*Kinetic Analyses.* Based on the results of the preliminary screening, UGT1A3, UGT1A9, UGT1A10-H, UGT2B4, UGT2B7 and UGT2B17 were selected for further kinetic analyses. Incubations were conducted as previously described using a protein concentration of 0.2 mg· mL<sup>-1</sup> and a minimum of seven different substrate concentrations, ranging from 1 μM to 3000 μM for each hrUGT assay. Reactions were terminated after a 20-minute incubation.

*Clopidogrel Carboxylic Acid Metabolism in HLM, HIM, hrUGT2B7 and hrUGT2B17.* In order to determine the maximal linear range of glucuronidation, depletion of 0.5 μM clopidogrel carboxylic acid and formation of clopidogrel acyl-β-D-glucuronide were measured in HLM, HIM, and recombinant UGT2B7 and UGT2B17 (0.4 and 0.8 mg· mL<sup>-1</sup>) for up to 90 minutes. This clopidogrel carboxylic acid concentration is within the clinically relevant range, since its average peak plasma concentration (C<sub>max</sub>) in the clinical data was 35 and 72 μM, corresponding to unbound concentrations (C<sub>max,u</sub>) of 0.7 and 1.4 μM for the 300 and 600 mg dose, respectively.

*Inhibition Experiments.* Clopidogrel carboxylic acid glucuronidation in HLM, HIM, UGT2B7 and UGT2B17 was investigated in the absence and presence of the potential UGT2B7 inhibitors aprepitant, fluconazole, gemfibrozil, ketamine and mefenamic acid, as well as the UGT2B17 inhibitor imatinib (Uchaipichat et al., 2006; Knights et al., 2009; Uchaipichat et al., 2011; House et al., 2015; Zhang et al., 2015). In addition, the selectivity of inhibition by gemfibrozil, mefenamic acid and imatinib was further investigated in UGT1A3, UGT1A9, UGT1A10-H and UGT2B4. Inhibition experiments were performed using clopidogrel carboxylic acid concentration of 0.5 μM for HLM and HIM incubations (0.4 mg· mL<sup>-1</sup>) and 5 μM for hrUGT incubations (0.2 mg· mL<sup>-1</sup>). Concentrations of aprepitant, fluconazole, gemfibrozil, ketamine, mefenamic acid and imatinib in the incubations were 10, 2500, 100, 500, 5 and 5 μM, respectively.



DMD #78162

Metabolism of Parent Clopidogrel in HLM and HIM. Clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide formation in HLM and HIM ( $0.8 \text{ mg} \cdot \text{mL}^{-1}$ ) was investigated by incubating  $10 \mu\text{M}$  or  $100 \mu\text{M}$  clopidogrel for 90 minutes. Incubation mixtures were prepared as described for UGT incubation conditions, with the exception that UDPGA was added to the mixture before preincubation and the reaction was initiated by the addition of the substrate.

Clopidogrel Carboxylic Acid Metabolism and CYP2C8 Inhibition in HLM. The formation of clopidogrel acyl- $\beta$ -D-glucuronide from clopidogrel carboxylic acid and the subsequent inactivation of CYP2C8 were studied in HLM using amodiaquine N-desethylation as a marker reaction for CYP2C8 activity. Briefly, incubation mixtures containing clopidogrel carboxylic acid ( $50 \mu\text{M}$ ) in HLM ( $0.5 \text{ mg} \cdot \text{mL}^{-1}$ ) were prepared as described previously. However, after preincubation for 5 minutes, a combined cofactor solution containing both  $5 \text{ mM}$  UDPGA (to initiate glucuronidation) and  $1 \text{ mM}$  NADPH (to initiate metabolism-dependent inactivation of CYP2C8 by clopidogrel acyl- $\beta$ -D-glucuronide) was added to the mixtures. At determined time points, aliquots of  $7.5 \mu\text{L}$  of the reaction mixture were transferred to other tubes containing amodiaquine ( $10 \mu\text{M}$ ) and NADPH ( $1 \text{ mM}$ ) in buffer in a final incubation volume of  $150 \mu\text{L}$  to measure CYP2C8 activity. Protein and inhibitor concentrations were thus diluted 20-fold and direct inhibition by clopidogrel acyl- $\beta$ -D-glucuronide was minimized by using an amodiaquine concentration higher than its  $K_m$  for CYP2C8. The reaction mixture was incubated for 2 minutes ( $37^\circ\text{C}$ , 300 rpm) and the reaction was stopped by mixing  $50 \mu\text{L}$  sample with  $150 \mu\text{L}$  of stop solution ( $0.3\%$  formic acid in acetonitrile:methanol:water 90:5:5 v/v/v) containing deuterium-labeled N-desethylamodiaquine as an internal standard. Samples were vortexed, kept on ice for at least 10 minutes and centrifuged ( $20\,800 \times g$  for 10 min). The supernatant was transferred to silanized glass tubes and evaporated to dryness under nitrogen. The

DMD #78162

residue was reconstituted with 50  $\mu\text{L}$  of mobile phase A/ mobile phase B (95:5, v/v) (see section “Quantification of drug concentrations”). To confirm inhibition by clopidogrel acyl- $\beta$ -D-glucuronide, controls without clopidogrel carboxylic acid and controls without either NADPH or UDPGA in the pre-dilution incubation mixture were prepared as above. Separate samples for clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide quantification were also collected directly after N-desethylamodiaquine sampling. The samples were treated and prepared as described for UGT incubation conditions.

*Quantification of Drug Concentrations.* The drug concentrations were measured with a Nexera X2 (Shimadzu, Kyoto, Japan) or an Agilent 1100 series liquid chromatograph (Agilent Technologies, Waldbronn, Germany) coupled to a 5500 Qtrap, API3000 or API2000 tandem mass spectrometer (AB Sciex, Toronto, Ontario, Canada). Clopidogrel carboxylic and clopidogrel acyl- $\beta$ -D-glucuronide were separated on a Sun Fire C18 analytical column (150  $\times$  2.1 mm, 3  $\mu\text{m}$  particle size; Waters, Millford, MA) using isocratic mobile phase conditions (2 mM ammonium acetate; pH 5.5:acetonitrile 58:44 v/v). The flow rate and the column oven temperature were set at 0.26  $\text{mL} \cdot \text{min}^{-1}$  and 30  $^{\circ}\text{C}$ . The mass spectrometer was operated in positive turbo ion spray mode with the target ion transitions ( $m/z$ ) of 308 to 198 and 484 to 308 for clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide, respectively. Deuterium-labeled clopidogrel carboxylic acid served as an internal standard for both analytes. The lower limits of quantitation of clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide were 0.0038  $\mu\text{M}$  and 0.0023  $\mu\text{M}$ . The chromatographic separation for N-desethylamodiaquine was performed on an Atlantis T3 column (100  $\times$  2.1 mm, 3  $\mu\text{m}$  particle size; Waters Corporation, Milford, MA) using gradient elution as previously described (Filppula et al., 2012). The mobile phases consisted of 0.3% formic acid in 5 mM ammonium formate (mobile phase A) and 0.3% formic acid in 90/5/5 acetonitrile/methanol/water (mobile phase B), and the limit of quantification for N-

DMD #78162

desethylamodiaquine was 0.001  $\mu\text{M}$ . The day-to-day coefficients of variation were below 15% at relevant concentrations for all analytes, except for the lowest quality control (3 nM) of N-desethylamodiaquine, whose coefficient of variation was 18%. None of the other drugs or drug metabolites interfered with the assays.

Data Analysis. The kinetics of clopidogrel acyl- $\beta$ -D-glucuronide formation were analyzed using SigmaPlot, version 13.0 (Systat Software, San Jose, CA, USA). Selection of the best-fit enzyme model was based on the Akaike information criterion, the  $r^2$  values, 95% confidence intervals (CI), and on the examination of Michaelis-Menten and Eadie-Hofstee plots. The data were analyzed with the following models:

#### Michaelis-Menten

$$v = \frac{V_{max} [S]}{K_m + [S]}$$

where  $v$  is the initial velocity of the enzyme reaction,  $V_{max}$  is the maximal reaction velocity,  $[S]$  is the substrate concentration, and  $K_m$  is the Michaelis-Menten constant.

#### Substrate inhibition

$$v = \frac{V_{max}}{1 + \frac{K_m}{[S]} + \frac{[S]}{K_i}}$$

where  $K_i$  represents the dissociation constant for the inhibitory substrate-enzyme-substrate ternary complex.

#### Sigmoidal (Hill)

$$v = \frac{V_{max} [S]^n}{K_m^n + [S]^n}$$

DMD #78162

where  $n$  is the Hill coefficient.

### Two binding sites

$$v = \frac{\frac{V_{max1}[S]}{K_{m1}} + \left(\frac{V_{max2}[S]^2}{K_{m1}K_{m2}}\right)}{1 + \frac{[S]}{K_{m1}} + \frac{[S]^2}{K_{m1}K_{m2}}}$$

where  $K_{m1}$  and  $K_{m2}$  represent the Michaelis-Menten constants for the binding of the substrate molecules to the first and second binding site, respectively (Korzekwa et al., 1998).

Intrinsic clearance for clopidogrel acyl- $\beta$ -D-glucuronide formation ( $CL_{int}$ ) was calculated according to  $CL_{int} = V_{max}/K_m$ . This equation can be used for determination of  $CL_{int}$  and reaction phenotyping when the substrate concentration is less than 10% of the  $K_m$ . In our clinical study, the average  $C_{max,u}$  was less than 10% of the lowest  $K_m$  of the recombinant UGTs. Likewise, the substrate concentrations used for  $CL_{int,u,dep}$  determination and the inhibition experiments in HLM and HIM were only 3% of the lowest  $K_m$ , corresponding to the clinically relevant concentration range. Pseudo-first-order depletion rate constants ( $k_{dep}$ ) were determined for the depletion of  $0.5 \mu\text{M}$  clopidogrel carboxylic acid in HLM and HIM using nonlinear regression analysis (SigmaPlot). The intrinsic clearance in depletion experiments was calculated as  $CL_{int \times dep} = k_{dep} / [M]$ , where  $[M]$  is the microsomal protein concentration (Venkatakrisnan et al., 2003). The relative contributions of UGT1A3, UGT1A9, UGT2B4, UGT2B7, and UGT2B17 in the hepatic metabolism of clopidogrel carboxylic acid were estimated from the determined  $CL_{int}$  values using a conversion factor, which was determined from previously published peptide-based quantification studies by dividing the molar abundancy of each UGT isoform in human liver microsomes with the molar abundancy of the respective hrUGT isoform in baculovirus infected insect cells (Supersomes) (Fallon et al., 2013a; Fallon et al., 2013b; Sato et al., 2014). The relative contribution of each UGT isoform in

DMD #78162

clopidogrel carboxylic acid glucuronidation was calculated by multiplying recombinant  $CL_{int}$  values with the respective conversion factor. The  $CL_{int, in vivo}$  value for the hepatic glucuronidation of clopidogrel carboxylic acid was calculated using the standard *in vitro-in vivo* scaling parameters of 40 mg of microsomal protein/g liver (Houston and Galetin, 2008) and 25.7 g of liver/kg body wt. (Davies and Morris, 1993).

### **Clopidogrel Pharmacokinetics and Pharmacogenetic Analysis in Healthy Volunteers**

*Subjects and Study Design.* A total of 106 healthy Finnish volunteers from eight of our previous or ongoing pharmacokinetic studies (49 women and 57 men; mean  $\pm$  S.D.: age  $24 \pm 4$  years, height  $175 \pm 9$  cm, weight  $71 \pm 13$  kg, and body mass index  $23 \pm 3$  kg/m<sup>2</sup>), including six drug-drug interaction studies and two genotype panel studies, were available for pharmacogenetic analysis (Supplementary Table 1) (Holmberg et al., 2014; Tornio et al., 2014; Itkonen et al., 2015; Tarkiainen et al., 2015; Itkonen et al., 2016; Holmberg et al., unpublished data; Itkonen et al., unpublished data). No individuals with a non-Caucasian background or excess relatedness were included in the study. During these studies, each subject was given a single 300 mg (n=49) or 600 mg (n=57) dose of clopidogrel in the morning after an overnight fast. Timed EDTA blood samples, including a sample for DNA extraction, were drawn before and at designated times after clopidogrel ingestion. Plasma concentrations of clopidogrel and its metabolites were quantified using LC/MS/MS, as described in the respective studies. The health of the subjects was confirmed by their medical history, physical examination, and routine laboratory tests before entering the study. All subjects had normal blood platelet counts and haemoglobin values. None was a tobacco smoker and none used any continuous medication (e.g. oral contraceptives). A written informed consent was obtained from all study participants for participation in pharmacogenetic studies and the studies

DMD #78162

were approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District and the Finnish Medicines Agency Fimea.

Pharmacokinetics. For the present analysis,  $C_{\max}$ , time to  $C_{\max}$  ( $t_{\max}$ ), the elimination half-life ( $t_{1/2}$ ) and the area under the plasma concentration–time curve from 0 h to 4 h ( $AUC_{0-4}$ ) of clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide were calculated for each of the 106 subjects using uniform noncompartmental methods with Phoenix WinNonlin, version 6.3 (Certara, St Louis, MO, USA). The clopidogrel acyl- $\beta$ -D-glucuronide to clopidogrel carboxylic acid plasma AUC ratio was used as an index of the rate of clopidogrel carboxylic acid glucuronidation. The concentration-time points that were available from all the eight studies (0, 1, 1.5, 2, 3 and 4 hours postdose) were used in the pharmacokinetic calculations.

DNA Extraction, Genotyping and Copy Number Determination. Genomic DNA was extracted using the Maxwell 16 LEV Blood DNA Kit on a Maxwell 16 Research automated nucleic acid extraction system (Promega, Madison, WI). The samples were genotyped for the *UGT2B7*\*2 allele by genotyping the rs7668258 (c.-161T>C) single nucleotide variation (SNV), which is in a complete linkage disequilibrium ( $r^2 = 1.00$ ) (1000 Genomes Project, [www.internationalgenome.org](http://www.internationalgenome.org)) with the rs7439366 (c.802T>C, p.Y268H) SNV defining \*2, with a TaqMan genotyping assay (C\_27827970\_40) on a QuantStudio™ 12K Flex Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA). The *UGT2B17*\*2 deletion allele was genotyped with the TaqMan Copy Number assay Hs03185327\_cn, targeting the *UGT2B17* intron 1 - exon 1 region (chr.4:68567750 on build GRCh38), with *RPPH1* (*Ribonuclease P RNA component H1*) as the reference gene, on the QuantStudio™ 12K Flex Real-Time PCR System.

DMD #78162

Statistical Analysis. The *in vitro* results are expressed as arithmetic means with S.D. The pharmacokinetic variables were logarithmically transformed before analysis and presented as geometric means with 95% CI. The comparisons between genotypes were carried out using forward stepwise linear regression with *UGT2B7* and *UGT2B17* genotypes, weight, body mass index, age, sex and dose as independent variables. Additive coding was employed for the genotypes. Differences were considered statistically significant when *P* was below 0.05. The data were analyzed using IBM SPSS Statistics, version 24 (Chicago, IL, USA).

DMD #78162

## Results

UGT Screening and Kinetic Analyses. Among the 13 UGT enzymes screened, UGT2B17 and UGT2B7 displayed the highest activities at 10  $\mu\text{M}$  clopidogrel carboxylic acid concentration, i.e. 39.3 and 16.9  $\text{pmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$  protein at 90 minutes, respectively (Figure 2). UGT1A3, UGT1A9, UGT1A10-H and UGT2B4 also showed significant activities, between 5% and 20% of the UGT2B17 rates. The glucuronidation activities of UGT1A4, UGT1A6, UGT1A7 and UGT2B15 were very low or negligible and these enzymes were thus excluded from detailed kinetic analyses. UGT1A1, UGT1A8, UGT1A10 and UGT2B10 did not form any detectable clopidogrel acyl- $\beta$ -D-glucuronide.

The kinetics of clopidogrel carboxylic acid glucuronidation by UGT1A3, UGT1A9, UGT2B7 and UGT2B17 followed the Michaelis-Menten model (Figure 3). For UGT1A10-H, several kinetic models gave a reasonable fit, and the Michaelis-Menten model was chosen based on confidence level in the parameter estimates. Clopidogrel carboxylic acid glucuronidation by UGT2B4 displayed non-hyperbolic kinetics and the best fit was obtained with the two binding sites model. The calculated kinetic parameters, including parameters that are not shown in Figure 3, are summarized in Table 1.

To allow estimation of the clinical relevance of each UGT in the metabolism of clopidogrel, we scaled the *in vitro*  $\text{CL}_{\text{int,u}}$  data to the average hepatic and intestinal microsomal intrinsic clearance on the basis of published protein expression data. Despite its weaknesses, this scaling method could be used to approximate the contributions of most UGTs identified in this study. UGT2B17 and UGT2B7 exhibited the highest  $\text{CL}_{\text{int,u}}$  values of clopidogrel carboxylic acid glucuronidation (Table 1). After abundance-based scaling, UGT2B7 was estimated to have the highest unbound intrinsic liver microsomal clearance ( $\text{CL}_{\text{int,u,HLM}}$ ), accounting for about 55-60% of the total (combined) intrinsic clearance ( $\text{CL}_{\text{int,u,HLM,tot}}$ ). UGT2B7 was followed by UGT1A9, UGT2B4 and UGT2B17,



DMD #78162

whose estimated combined contribution to the metabolism of clopidogrel carboxylic acid was approximately 40% of the  $CL_{int,u,HLM,tot}$ . However, the estimated contribution of UGT1A3 was only minor. In the intestine, the scaled unbound intrinsic clearance ( $CL_{int,u,HIM}$ ) of UGT2B17 accounted for 87% of the total unbound intrinsic clearance ( $CL_{int,u,HIM,tot}$ ), while the contribution of UGT2B7 to  $CL_{int,u,HIM,tot}$  was only about 10%, and those of UGT1A10-H and UGT1A3 were <1%.

*Clopidogrel Carboxylic Acid Depletion in HLM, HIM, UGT2B7 and UGT2B17.* In a substrate depletion experiment, approximately 15-30% of the initial clopidogrel carboxylic acid concentration (0.5  $\mu$ M) was consumed during a 90 minute incubation with UDPGA in HLM or HIM. In recombinant UGT2B7 and UGT2B17, 5-10% of the initial substrate concentration was consumed during similar incubations. In all experiments, depletion was log-linear until at least 30 minutes, allowing for estimation of the intrinsic clearance from the results (Table 2).

*Inhibition of Clopidogrel Carboxylic Acid Glucuronidation by Chemical Inhibitors of UGTs.* In preliminary experiments in hrUGT2B7 and hrUGT2B17, aprepitant (10  $\mu$ M), fluconazole (2.5 mM) and ketamine (500  $\mu$ M) inhibited both UGT2B7 and UGT2B17-mediated clopidogrel carboxylic acid glucuronidation by >90% (Figure 4A). Gemfibrozil (100  $\mu$ M) showed very strong UGT2B7 inhibition (100%), but also moderate inhibition (30-70%) of other UGTs, including UGT1A9, UGT1A10-H, UGT2B4 and UGT2B17 (Figure 4B). Mefenamic acid (5  $\mu$ M) had a strong inhibitory effect on both UGT2B7 (95%) and UGT1A9 (98%), but no inhibitory effect on UGT1A3, UGT2B4 and UGT2B17. In contrast, 5  $\mu$ M imatinib strongly and selectively inhibited UGT2B17 activity (100% inhibition), with only a small inhibitory effect on UGT2B7 (16% inhibition) and a moderate effect on UGT1A10-H (59%).

DMD #78162

The UGT2B7 and UGT1A9 inhibitor mefenamic acid inhibited clopidogrel acyl- $\beta$ -D-glucuronide formation in HLM by 38% but only slightly in HIM (12%), whereas gemfibrozil inhibited clopidogrel glucuronidation both in HLM and HIM (34-43%) (Figure 4C). The preferential UGT2B17 inhibitor imatinib inhibited clopidogrel carboxylic acid glucuronidation only in HIM (by 85%). The nonselective UGT2B inhibitors aprepitant, fluconazole and ketamine substantially inhibited clopidogrel acyl- $\beta$ -D-glucuronide formation both in HLM and HIM (by 60-90%).

*Metabolism of Parent Clopidogrel in HLM and HIM.* During incubation of 10  $\mu$ M parent clopidogrel in HLM, clopidogrel carboxylic acid concentration rose to 8.9  $\mu$ M rapidly, in 15 minutes, followed by a gradual decrease (Figure 5A). At the same time, clopidogrel carboxylic acid was further metabolized to clopidogrel acyl- $\beta$ -D-glucuronide, whose concentration reached 19% of that of clopidogrel carboxylic acid at 90 minutes (Figure 5B). In HIM, the formation of clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide from 10  $\mu$ M clopidogrel was substantially slower than in HLM. At 90 minutes, clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide concentrations were 1.0  $\mu$ M and 0.06  $\mu$ M, respectively (Figure 5A, 5B). After incubating 100  $\mu$ M clopidogrel in HIM for 90 minutes, clopidogrel carboxylic acid concentration rose to 4.1  $\mu$ M, whereas the concentration of clopidogrel acyl- $\beta$ -D-glucuronide rose to the same level (0.06  $\mu$ M) only as in the experiment with 10  $\mu$ M clopidogrel (Figure 5C, 5D). Coincubation with 5  $\mu$ M imatinib in HIM did not affect clopidogrel carboxylic acid formation but markedly reduced clopidogrel acyl- $\beta$ -D-glucuronide formation (by 62% at 90 minutes) (Figure 5D).

DMD #78162

*UGT-mediated Bioactivation of Clopidogrel Carboxylic Acid and Subsequent Inactivation of CYP2C8.* Preincubation of 50  $\mu$ M clopidogrel carboxylic acid for 90 minutes in HLM in the presence of UDPGA or a combined cofactor solution containing both UDPGA and NADPH, produced approximately 19  $\mu$ M clopidogrel acyl- $\beta$ -D-glucuronide. Following preincubation of clopidogrel carboxylic acid with both UDPGA and NADPH for 90 minutes, amodiaquine N-desethylation (CYP2C8 marker reaction) was inhibited by 53% (Figure 6). No inhibition of amodiaquine N-desethylation could be observed when amodiaquine was incubated with a corresponding sample from preincubation mixtures containing only either one of the two cofactors.

*Clopidogrel Pharmacokinetic and Pharmacogenetic Analysis in Healthy Volunteers.* Linear regression analysis of the pharmacokinetic data obtained in 106 healthy volunteers revealed that of the tested genetic covariates, the *UGT2B17\*2* deletion allele was independently associated with pharmacokinetic variables of clopidogrel carboxylic acid and its acyl- $\beta$ -D-glucuronide. In addition, clopidogrel dose was independently associated with the AUC and AUC-ratio values of these clopidogrel metabolites ( $P < 0.05$ ). Each *UGT2B17\*2* deletion allele reduced the clopidogrel acyl- $\beta$ -D-glucuronide to clopidogrel carboxylic acid plasma AUC<sub>0.4</sub> ratio by 10.1% (95% CI, 1.7% - 17.8%;  $P = 0.021$ ) (Figure 7A). This AUC-ratio was 47% higher with the 600 mg dose than with the 300 mg dose of clopidogrel (95% CI, 28% - 68%;  $P < 0.001$ ). Moreover, *UGT2B17\*2* had a significant association with the  $t_{1/2}$  of clopidogrel carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide and the AUC<sub>0.4</sub> of clopidogrel acyl- $\beta$ -D-glucuronide (Figure 7B). Each *UGT2B17\*2* allele prolonged the  $t_{1/2}$  of clopidogrel carboxylic acid by 8.7% (95% CI, 2.2% - 15.7%;  $P = 0.008$ ) and the  $t_{1/2}$  of clopidogrel acyl- $\beta$ -D-glucuronide by 6.5% (95% CI, 0.34% - 13.0%;  $P = 0.039$ ) and decreased the AUC<sub>0.4</sub> of clopidogrel acyl- $\beta$ -D-glucuronide by 11.9% (95% CI, 1.1% - 21.5%;  $P = 0.032$ ). On the other hand, the \*2 polymorphism in the *UGT2B7* gene did not have a significant association with the AUC<sub>0.4</sub> or  $t_{1/2}$  values of clopidogrel, the active metabolite, clopidogrel

DMD #78162

carboxylic acid and clopidogrel acyl- $\beta$ -D-glucuronide or with the clopidogrel acyl- $\beta$ -D-glucuronide to clopidogrel carboxylic acid plasma AUC ratio.

DMD #78162

## Discussion

In the present study, we investigated the glucuronidation of clopidogrel carboxylic acid *in vitro*, and assessed the relative contributions of the different UGT enzymes to clopidogrel acyl- $\beta$ -D-glucuronide formation by using two *in vitro* approaches. Both an approach with chemical UGT inhibitors in HLMs and a scaling approach of recombinant UGT mediated clearances using peptide-based quantification data from previous publications (Fallon et al., 2013a; Fallon et al., 2013b; Sato et al., 2014) were consistent with an important role of UGT2B7 and UGT2B17 in the glucuronidation of clopidogrel carboxylic acid. In addition, UGT1A3, UGT1A9, UGT1A10-H and particularly UGT2B4 were estimated to participate in clopidogrel carboxylic acid glucuronidation. The role of UGT2B17 could also be verified in a clinical pharmacogenetic study.

Fluconazole and ketamine strongly inhibit UGT2B4, UGT2B7 and UGT2B17, with only minor effects on other relevant UGTs (Uchaipichat et al., 2006; Raungrut et al., 2010; Uchaipichat et al., 2011; House et al., 2015). In HLM, they reduced clopidogrel carboxylic acid glucuronidation by up to 90%, suggesting that collectively, UGT2B4, UGT2B7 and UGT2B17 are responsible for the majority of clopidogrel acyl- $\beta$ -D-glucuronide formation in the liver. Furthermore, the nonselective UGT2B7 inhibitors mefenamic acid and gemfibrozil inhibited clopidogrel carboxylic acid glucuronidation in HLM by about 40%. Accordingly, UGT2B7 is likely to play a large role in the formation of clopidogrel acyl- $\beta$ -D-glucuronide in the liver. On the other hand, the UGT2B17 inhibitor imatinib had practically no effect on clopidogrel carboxylic acid glucuronidation, suggesting a very small role for UGT2B17 in the liver.

In the liver, UGT2B7, UGT2B4 and UGT1A9 are relatively abundant, whereas the expression of UGT2B17 is low (Oda et al., 2012; Achour et al., 2014; Sato et al., 2014). Consequently, the abundancy-based scaling suggested that UGT2B7 accounts for almost 60% of the total unbound hepatic microsomal intrinsic clearance of clopidogrel carboxylic acid, while particularly UGT2B4,

DMD #78162

but also UGT2B17 and UGT1A9 account for the remaining  $CL_{int,u,HLM,tot}$ . This result is in agreement with the inhibition results. Yet, considering the effects of the various UGT2B inhibitors, this scaling probably slightly overestimated the contributions of UGT2B7 and UGT1A9 and underestimated the contribution of UGT2B4.

UGT2B17, UGT2B7 and UGT1A10 are expressed in the intestinal wall, but most other relevant UGTs are virtually absent (Sato et al., 2014). The strong (85%) inhibition of clopidogrel acyl- $\beta$ -D-glucuronide formation by the UGT2B17 inhibitor imatinib in HIM indicates that UGT2B17 is mostly responsible for clopidogrel carboxylic acid metabolism in the intestinal wall. Since UGT1A9 is only minimally expressed in enterocytes (Oda et al., 2012), the minor (12%) inhibition by the UGT2B7 and UGT1A9 inhibitor mefenamic acid in HIM suggests that also UGT2B7 has a small role. In excellent agreement, the scaling approach estimated a major role for UGT2B17 in the unbound intestinal intrinsic clearance, UGT2B7 having a less significant role. In addition to these UGT2B enzymes, UGT1A10 may slightly contribute to the metabolism of clopidogrel carboxylic acid in the intestinal wall, since imatinib weakly inhibits UGT1A10 and the scaling suggested a minimal role for UGT1A10 in the  $CL_{int,u,HIM,tot}$ .

Analysis of clinical data provided the final approach to investigate the contributions of UGT2B7 and UGT2B17 to the glucuronidation of clopidogrel carboxylic acid. No statistically significant associations between *UGT2B7* variants and clopidogrel pharmacokinetics; were observed. However, the common *UGT2B7*\*2 allele has rarely had any effect on the glucuronidation kinetics of UGT2B7 substrates and is thought to have little impact on enzyme activity (Bhasker et al., 2000; Peterkin et al., 2007; Parmar et al., 2011; Rae et al., 2012). Therefore, the clinical data do not allow direct estimation of the contribution of UGT2B7 to clopidogrel metabolism.

In contrast to *UGT2B7*, there is a common deletion in the *UGT2B17* gene, which leads to complete UGT2B17 deficiency (Murata et al., 2003). The absence of UGT2B17 due to homozygous

DMD #78162

deletion of the *UGT2B17* gene is common in Caucasian and African populations (~10-40%) and very frequent in East Asia (up to ~90%) (Wilson et al., 2004; Jakobsson et al., 2006; Xue et al., 2008; Chen et al., 2010; Giroux et al., 2012). As expected, the *UGT2B17* deletion was common in our Finnish population, with an allele frequency of 45%. Moreover, clopidogrel acyl- $\beta$ -D-glucuronide formation was impaired in carriers of the deletion, leading to a 10% or 19% lower clopidogrel acyl- $\beta$ -D-glucuronide to clopidogrel carboxylic acid plasma AUC<sub>0.4</sub> ratio in heterozygous and homozygous carriers, respectively, than in individuals carrying two functional copies of *UGT2B17*. Given that homozygous carriers of the deletion lack any metabolic activity by *UGT2B17*, the results suggest that the combined contribution of intestinal and hepatic *UGT2B17* to clopidogrel carboxylic acid glucuronidation is about 10% in heterozygous carriers and 20% in noncarriers, leaving 90% or 80% to other UGTs, respectively. As the *in vitro* findings indicate that *UGT2B17* is largely responsible for clopidogrel carboxylic acid glucuronidation in the intestinal wall, with about 10% contribution in the liver, it could be estimated that up to about 10% of clopidogrel acyl- $\beta$ -D-glucuronide is formed in the intestine, depending on *UGT2B17* genotype. Moreover, as both clopidogrel carboxylic acid and acyl- $\beta$ -D-glucuronide were formed from clopidogrel in HIM, there seems to be an interplay of *CES1* and *UGT2B17* in the intestinal wall.

*CYPs* and *UGTs* are located intracellularly on opposite sides of the endoplasmic membranes and there is evidence for a protein-protein interplay between certain *UGT* and *CYP* enzymes (Takeda et al., 2005; Ishii et al., 2010; Miyauchi et al., 2015). This interplay and the close proximity of the enzymes could theoretically facilitate interaction of glucuronide metabolites with *CYP* enzymes. In the present study, we demonstrated UDPGA-dependent formation of clopidogrel acyl- $\beta$ -D-glucuronide (19  $\mu$ M in 90 min) and simultaneous NADPH-dependent 60% inhibition of *CYP2C8* activity in HLM. This *CYP2C8* inhibitory effect was slightly stronger than what we expected on the basis of the obtained clopidogrel acyl- $\beta$ -D-glucuronide concentrations, suggesting that the proximity of *UGTs* and *CYP2C8* may facilitate the access of the acyl- $\beta$ -D-glucuronide to

DMD #78162

CYP2C8. Such a mechanism might also partially explain why the clopidogrel-repaglinide interaction was best predicted, when the unbound concentration of clopidogrel acyl- $\beta$ -D-glucuronide was assumed to be almost 20 times higher in hepatocytes than in plasma (Tornio et al., 2014).

In conclusion, the present study indicates that UGT2B7 is the main enzyme involved in clopidogrel carboxylic acid glucuronidation in the liver, while at least UGT2B4, and possibly also UGT1A9 and UGT2B17 play a smaller role. On the other hand, UGT2B17 has a major role in the intestinal metabolism of clopidogrel. Consequently, the formation of clopidogrel acyl- $\beta$ -D-glucuronide is impaired in carriers of the *UGT2B17* gene deletion. The findings may have implications with regard to drug-drug interactions caused by inactivation of CYP2C8 by clopidogrel acyl- $\beta$ -D-glucuronide.



DMD #78162

## **Acknowledgments**

We thank Jouko Laitila, Eija Mäkinen-Pulli and Lisbet Partanen for their skillful technical assistance.

DMD #78162

## **Authorship Contributions**

*Conceived and designed the experiments:* Kahma, Filppula and Backman

*Conducted the laboratory work:* Kahma, Filppula, Neuvonen M. and Tarkiainen

*Conducted the clinical studies:* Tarkiainen, Tornio, Holmberg, Itkonen, Neuvonen P.J., Niemi and Backman

*Performed the data analysis:* Kahma, Filppula, Tarkiainen and Niemi

*Contributed new reagents:* Finel

*Involved in analysis and interpretation of the data:* Finel, Niemi and Backman

*Wrote or contributed to the writing of the manuscript:* all authors

DMD #78162

## References

- Achour B, Rostami-Hodjegan A, and Barber J (2014) Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. *Biopharm Drug Dispos* **35**: 353-361.
- Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. *Pharmacogenetics* **10**: 679-685.
- Chen BL, Chen Y, Tu JH, Li YL, Zhang W, Li Q, Fan L, Tan ZR, Hu DL, Wang D, Wang LS, Ouyang DS, and Zhou HH (2009) Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. *J Clin Pharmacol* **49**: 574-581.
- Chen G, Giambone NE, Jr, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, and Lazarus P (2010) Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. *Cancer Res* **70**: 7543-7552.
- Clarke TA and Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. *Drug Metab Dispos* **31**: 53-59.
- Dansette PM, Rosi J, Bertho G, and Mansuy D (2012) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. *Chem Res Toxicol* **25**: 348-356.
- Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. *Pharm Res* **10**: 1093-1095.
- Fallon JK, Neubert H, Goosen TC, and Smith PC (2013a) Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using

DMD #78162

nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring. *Drug Metab Dispos* **41**: 2076-2080.

Fallon JK, Neubert H, Hyland R, Goosen TC, and Smith PC (2013b) Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. *J Proteome Res* **12**: 4402-4413.

Filppula AM, Laitila J, Neuvonen PJ, and Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. *Br J Pharmacol* **165**: 2787-2798.

Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, Wiggins KL, Tamraz B, Kwok PY, Totah RA, and Psaty BM (2012) A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. *Clin Pharmacol Ther* **91**: 896-904.

Frelinger AL, 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, and Michelson AD (2012) A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. *J Am Coll Cardiol* **59**: 1304-1311.

Giroux S, Bussieres J, Bureau A, and Rousseau F (2012) UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women. *Osteoporos Int* **23**: 1163-1170.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccchia R, Valente S, Antonucci D, Abbate R, and Gensini GF (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response

DMD #78162

variability to dual antiplatelet treatment in high-risk vascular patients. *Pharmacogenet Genomics* **17**: 1057-1064.

Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, and Ikeda T (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. *Drug Metab Dispos* **37**: 2145-2152.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Buttner HJ, and Neumann FJ (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. *J Am Coll Cardiol* **55**: 2427-2434.

Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, and Niemi M (2014) Grapefruit juice inhibits the metabolic activation of clopidogrel. *Clin Pharmacol Ther* **95**: 307-313.

House L, Ramirez J, Seminerio M, Mirkov S, and Ratain MJ (2015) In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. *Xenobiotica* **45**: 990-998.

Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. *Curr Drug Metab* **9**: 940-951.

Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. *Blood* **108**: 2244-2247.

DMD #78162

Ishii Y, Takeda S, and Yamada H (2010) Modulation of UDP-glucuronosyltransferase activity by protein-protein association. *Drug Metab Rev* **42**: 145-158.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, and Backman JT (2016) Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. *Drug Metab Dispos* **44**: 1364-1371.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, and Backman JT (2015) Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. *Drug Metab Dispos* **43**: 1655-1660.

Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, Roh HK, Carlstrom K, and Rane A (2006) Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. *J Clin Endocrinol Metab* **91**: 687-693.

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, and Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. *Drug Metab Dispos* **38**: 92-99.

Knights KM, Winner LK, Elliot DJ, Bowalgaha K, and Miners JO (2009) Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. *Br J Clin Pharmacol* **68**: 402-412.

Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models:

DMD #78162

evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.

*Biochemistry* **37**: 4137-4147.

Kuuranne T, Kurkela M, Thevis M, Schanzer W, Finel M, and Kostianen R (2003)

Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. *Drug Metab Dispos* **31**: 1117-1124.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, and Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med* **360**: 354-362.

Miyauchi Y, Nagata K, Yamazoe Y, Mackenzie PI, Yamada H, and Ishii Y (2015) Suppression of cytochrome P450 3A4 function by UDP-glucuronosyltransferase 2B7 through a protein-protein interaction: cooperative roles of the cytosolic carboxyl-terminal domain and the luminal anchoring region. *Mol Pharmacol* **88**: 800-812.

Murata M, Warren EH, and Riddell SR (2003) A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. *J Exp Med* **197**: 1279-1289.

Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, and Ikeda T (2009) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. *Xenobiotica* **39**: 836-843.

Oda S, Nakajima M, Hatakeyama M, Fukami T, and Yokoi T (2012) Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. *Drug Metab Dispos* **40**: 1620-1627.

DMD #78162

- Parmar S, Stingl JC, Huber-Wechselberger A, Kainz A, Renner W, Langsenlehner U, Krippel P, Brockmoller J, and Haschke-Becher E (2011) Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. *Breast Cancer Res* **13**: R57.
- Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, and Myrand SP (2007) Limited influence of UGT1A1\*28 and no effect of UGT2B7\*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. *Br J Clin Pharmacol* **64**: 458-468.
- Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, and ATAC trialists (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. *J Natl Cancer Inst* **104**: 452-460.
- Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, and Miners JO (2010) In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. *J Pharmacol Exp Ther* **334**: 609-618.
- Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. *J Pharmacol Exp Ther* **308**: 189-197.
- Sato Y, Nagata M, Tetsuka K, Tamura K, Miyashita A, Kawamura A, and Usui T (2014) Optimized methods for targeted peptide-based quantification of human uridine 5'-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry. *Drug Metab Dispos* **42**: 885-889.



DMD #78162

Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, and Herbert JM

(2000) Identification and biological activity of the active metabolite of clopidogrel. *Thromb Haemost* **84**: 891-896.

Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrlor K, Morath T, Schomig A, Kastrati A,

and von Beckerath N (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* **30**: 916-922.

Silvestro L, Gheorghe M, Iordachescu A, Ciuca V, Tudoroni A, Rizea Savu S, and Tarcomnicu I

(2011) Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. *Anal Bioanal Chem* **401**: 1023-1034.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J,

Danchin N, Becquemont L, and French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009) Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med* **360**: 363-375.

Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, and Yamada H

(2005) Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. *Mol Pharmacol* **67**: 665-672.

Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B

(2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. *J Pharmacol Exp Ther* **319**: 1467-1476.

DMD #78162

- Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, and Niemi M (2015) Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. *Clin Pharmacol Ther* **97**: 650-658.
- Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyronen TH, Tapaninen T, Neuvonen PJ, Niemi M, and Backman JT (2014) Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. *Clin Pharmacol Ther* **96**: 498-507.
- Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, and Laine K (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. *Clin Pharmacol Ther* **77**: 553-559.
- Uchaipichat V, Raungrut P, Chau N, Janchawee B, Evans AM, and Miners JO (2011) Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. *Drug Metab Dispos* **39**: 1324-1328.
- Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. *Br J Clin Pharmacol* **61**: 427-439.
- Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. *Curr Drug Metab* **4**: 423-459.

DMD #78162

Wilson W,3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, Gilmore RC, Valladeras IC, Wright CC, Threadgill DW, and Grant DJ (2004) Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. *Genomics* **84**: 707-714.

Xue Y, Sun D, Daly A, Yang F, Zhou X, Zhao M, Huang N, Zerjal T, Lee C, Carter NP, Hurles ME, and Tyler-Smith C (2008) Adaptive evolution of UGT2B17 copy-number variation. *Am J Hum Genet* **83**: 337-346.

Zhang N, Liu Y, and Jeong H (2015) Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases. *Sci Rep* **5**: 17778.

DMD #78162

## Footnotes

This study has been financially supported by grants from the Academy of Finland [Grant decision 278123, 2014] and the Sigrid Juselius Foundation [Grant 4704583] (Helsinki, Finland) and by State funding for university-level health research.

This work was previously presented as posters at the 11<sup>th</sup> International Meeting of the International Society for the Study of Xenobiotics (ISSX), June 12-16, 2016, Busan, South Korea and at the 13<sup>th</sup> Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), June 24-27, 2017, Prague, Czech Republic.

DMD #78162

## Figure Legends

**Figure 1.** Metabolic pathways of clopidogrel.

**Figure 2.** Glucuronidation of 10  $\mu\text{M}$  clopidogrel carboxylic acid in human recombinant UGTs.

Each column represents the mean  $\pm$  S.D. of duplicate incubations.

**Figure 3.** Enzyme kinetics of clopidogrel carboxylic acid glucuronidation by human recombinant UGT1A3 (A), UGT1A9 (B), UGT1A10-H (C), UGT2B4 (D), UGT2B7 (E) and UGT2B17 (F).

Eadie–Hofstee plots are shown as insets. Each point represents the mean  $\pm$  S.D. of at least duplicate incubations.

**Figure 4.** Effects of chemical inhibitors on clopidogrel carboxylic acid glucuronidation *in vitro*.

Aprepitant (10  $\mu\text{M}$ ), fluconazole (2.5 mM) and ketamine (500  $\mu\text{M}$ ) (A) and gemfibrozil (100  $\mu\text{M}$ ), mefenamic acid (5  $\mu\text{M}$ ) and imatinib (5  $\mu\text{M}$ ) (B) were incubated with 5  $\mu\text{M}$  clopidogrel carboxylic acid in human recombinant UGTs (0.2 mg  $\cdot$  mL<sup>-1</sup>) or 0.5  $\mu\text{M}$  clopidogrel carboxylic acid in HLM and HIM (0.4 mg  $\cdot$  mL<sup>-1</sup>) (C) for 15 minutes. Complete inhibition of UGT2B7 was caused by gemfibrozil (100  $\mu\text{M}$ ) and of UGT2B17 by imatinib (5  $\mu\text{M}$ ). Each column represents the mean  $\pm$  S.D. of duplicate incubations.

**Figure 5.** Metabolism of 10  $\mu\text{M}$  clopidogrel in HLM and HIM (A, B) and 100  $\mu\text{M}$  clopidogrel in HIM (C, D) (0.8 mg  $\cdot$  mL<sup>-1</sup>). Each point represents the mean  $\pm$  S.D. of duplicate incubations.

DMD #78162

**Figure 6.** The effect of a preincubation containing UDPGA, NADPH and clopidogrel carboxylic acid ( $50 \mu\text{M}$ ) on the metabolism of amodiaquine ( $10 \mu\text{M}$ ) by CYP2C8. Each column represents the mean  $\pm$  S.D. of duplicate incubations.

**Figure 7.** Effect of *UGT2B17* copy number variation on the dose-adjusted clopidogrel acyl- $\beta$ -D-glucuronide to clopidogrel carboxylic acid plasma  $\text{AUC}_{0-4}$  ratio (A) and the dose-adjusted clopidogrel acyl- $\beta$ -D-glucuronide  $\text{AUC}_{0-4}$  (B). Central line shows the geometric mean and the bars show the 95% confidence intervals. Dose adjustments to the 300 mg dose were carried out on the basis of the corresponding regression coefficients.

## Tables

**Table 1.** Kinetic parameters (mean  $\pm$  S.D.) of clopidogrel carboxylic acid glucuronidation by UGT1A3, UGT1A9, UGT1A10-H, UGT2B4, UGT2B7 and UGT2B17 and scaling of their contributions to the total microsomal intrinsic clearance in the liver and intestine.

	UGT1A3	UGT1A9	UGT1A10-H	UGT2B4	UGT2B7	UGT2B17
Model	MM	MM	MM	Two binding sites	MM	MM
$V_{\max}$ ( $\mu\text{mol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ )	595 $\pm$ 28	61.5 $\pm$ 2.8	28.7 $\pm$ 1.4	8.57 $\pm$ 1.77 ( $V_{\max 1}$ ) 131 $\pm$ 5.97 ( $V_{\max 2}$ )	50.5 $\pm$ 1.7	511 $\pm$ 11
$K_m$ ( $\mu\text{M}$ )	1980 $\pm$ 150	74.8 $\pm$ 14.5	307 $\pm$ 38	19.0 $\pm$ 8.50 ( $K_{d1}$ ) 2340 $\pm$ 274 ( $K_{d2}$ )	20.9 $\pm$ 3.2	181 $\pm$ 12
$CL_{\text{int,u}}$ ( $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ )	0.301	0.822	0.0936	0.451 ( $CL_{\text{int,u}}$ ) 0.0560 ( $CL_{\text{int,u}}$ )	2.42	2.82
<u>Liver</u>						
$CL_{\text{int,u,HLM}}$ Sato <sup>a</sup> ( $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg HLM}^{-1}$ )	0.00380 (1.3%)	0.0257 (9.1%)	N/A	0.0577 (20.3%)	0.157 (55.3%)	0.0394 (13.9%)
$CL_{\text{int,u,HLM}}$ Fallon <sup>b</sup> ( $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg HLM}^{-1}$ )	0.00528 (1.6%)	0.0395 (12.3%)	N/A	0.0528 (16.5%)	0.194 (60.4%)	0.0293 (9.1%)
<u>Intestine</u>						
$CL_{\text{int,u,HIM}}$ Sato <sup>a</sup> ( $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg HIM}^{-1}$ )	0.000380 (0.4%)	N/A	0.000740 (0.7%)	N/A	0.0126 (12.0%)	0.0912 (87.0%)

<sup>a</sup> Scaling of intrinsic clearance values was calculated using UGT abundancies in the liver and intestine published by Sato et al. (2014).

<sup>b</sup> Scaling of intrinsic clearance values was calculated using UGT abundancies in the liver published by Fallon et al. (2013a; 2013b)


DMD #78162

**Table 2.** Kinetic parameters of clopidogrel carboxylic acid ( $0.5 \mu\text{M}$ ) depletion in HLM, HIM and human recombinant UGT2B7 and UGT2B17 at protein concentration of  $0.4 \text{ mg} \cdot \text{mL}^{-1}$ .


	HLM	HIM	UGT2B7	UGT2B17
$k_{\text{dep}}$ ( $\text{l} \cdot \text{min}^{-1}$ )	0.00215	0.00151	0.000405	0.000718
$\text{CL}_{\text{int,u,dep}}$ ( $\mu\text{L} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ )	5.38	3.77	3.35	1.80
$\text{CL}_{\text{int,in vivo}}$ ( $\text{mL} \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$ )	5.53	N/A	N/A	N/A









## Figures




**Figure 1.**



**Figure 2.**





**Figure 3.**





**Figure 4.**


### 10 $\mu\text{M}$ Clopidogrel




### 100 $\mu\text{M}$ Clopidogrel



**Figure 5.**



**Figure 6.**



**Figure 7.**